Services:
Whole Body Autoradiography
In Vitro Autoradiography
In Vivo Receptor Occupancy
Radioligand Binding Assay
 
 

In Vitro Receptor Occupancy: Radioligand Binding Assay

 

Overview:  A competitive radioligand binding assay enables the IC50 and Ki value for the receptor-drug interaction to be determined by measuring the ability of increasing concentations of the (non-radioactive) test drug to compete with binding of a radioactively-labeled drug for the targeted receptor in a homogenate.  Alternatively, the receptor density (Bmax) in the tissue can be obtained by using a saturation radioligand binding assay in which receptor binding is determined in the presence of increasing concentrations of the radioligand alone.

 

Radioligand binding assay protocol (competition assay format):  Incubate a range of concentrations of the test drug together with a radioligand for the receptor and a tissue homogenate or cell membrane homogenate containing the receptor.  After equilibrium has been reached, separate bound from free radioligand using a 36-well filtration apparatus.  Count radioactivity on the filters and plot results to obtain IC50 and Ki values for the test drug.

 

Testing:  For competition assays, an IC50 and Ki value is obtained for each test drug by measuring binding over 10 drug concentrations over a three log unit range, with triplicate determinations at each concentration and three tubes to determine non-specific binding (= 36 assay tubes).  For protocols where the goal instead is to determine receptor density (Bmax) in the tissue, a hot saturation approach is used.  Binding is measured using 6 concentrations of the radioligand over a two log unit range, with triplicate determinations at each concentration and three tubes at each concentration to determine non-specific binding (= 36 assay tubes). 

 

Assay information:  Our receptor binding assays are conducted on a custom basis.  Literature-based protocols for the assay conditions, including radioligand, receptor preparation and reference drug will be used where available and the protocol approved by the client prior to starting work.  At least one reference compound will be included for each assay for assay validation. 

 

Example data:

Competitive radioligand binding assay.  Displacement of [3H]SR141716A binding to CB1 cannabinoid receptors in a mouse brain homogenate by the cannabinoid agonists AM2233 and WIN55212-2.  Displacement curves are shown fit to a two-site model with Ki values of 0.08 nM and 17 nM for AM2233 and 2 nM and 43 nM for WIN55212-2.
 
InvivoPharm Inc: Radioligand binding assay CRO service Copyright © 2009 InvivoPharm Inc